UnitedHealth Group Inc. (UNH) Reports Healthy Q2 Earnings

UnitedHealth Group IncUnitedHealth Group Inc. (NYSE:UNH) looks to be firing on nearly all cylinders in 2013. The nation’s largest health insurer reported strong second-quarter earnings before the market opened today. Shares shot up 5% in early trading. Here are the highlights from UnitedHealth Group Inc. (NYSE:UNH)’s results.

By the numbers
Net earnings for the quarter totaled $1.4 billion, or $1.40 per share. This reflects a 10% year-over-year increase on a per-share basis. It also easily surpassed Wall Street estimates of $1.25 per share. Earnings from operations came in at $2.4 billion, an increase of 8% compared to the second quarter from the prior year.

UnitedHealth Group Inc. (NYSE:UNH) reported second quarter revenue of $30.4 billion, up 12% from the same quarter in 2012. The average estimate of analysts polled by Thomson was $30.5 billion.

The company’s medical care ratio increased by 20 basis points year-over-year to 81.5%. UnitedHealth attributed this rise to higher revenue growth in government programs.

UnitedHealth Group Inc. (NYSE:UNH) also announced a nice improvement in its operating cost ratio. The ratio climbed 90 basis points from the second quarter of 2012 to 15.9% for the past quarter.

Behind the numbers
Several factors contributed to the healthy results reported by the insurer. None was more important than the rapid growth for Optum, UnitedHealth’s health services business unit.

Optum’s revenue jumped 21% year-over-year to $8.8 billion. Earnings from operations climbed to $536 million, a whopping 68% increase from the same period last year. Without Optum, UnitedHealth Group Inc. (NYSE:UNH)’s total net earnings would have decreased.

Every area within Optum performed well, with all businesses seeing double-digit growth in revenue and earnings from operations. Pharmacy benefits manager OptumRx had especially strong results. The unit continued to insource UnitedHealthcare pharmacy customers, as well as bring in new external customers. These efforts led to a 23% year-over-year increase in revenue and a 51% increase in earnings from operations.

The health insurance side of UnitedHealth Group’s business, UnitedHealthcare, saw revenue climb 11% year-over-year to $28.3 billion. This increase stemmed largely from strong enrollment growth for its commercial insurance, especially in fee-based insurance and the addition of TRICARE.

However, earnings for UnitedHealthcare of $1.9 billion in the second quarter were the same as the same period last year. This flatness resulted in large part from Medicare payment reductions.

International business kicked in $1.6 billion in revenue for the second quarter. UnitedHealth’s acquisition of Amil, Brazil’s largest health care company, made a big difference.

Looking ahead
The positive second-quarter results led UnitedHealth Group Inc. (NYSE:UNH) to affirm its full-year revenue projections of $122 billion. The company also tightened earnings guidance, providing a revised full-year net earnings range of $5.35 to $5.50 per share.

I suspect that Optum will continue to carry the company in the months ahead. Strong revenue and earnings growth in this lucrative side of the business should power UnitedHealth shares along.

My view is that, barring major macroeconomic woes, the stock will experience solid, although perhaps not spectacular, gains through the remainder of this year and into 2014. With a 1.6% dividend yield to boot, UnitedHealth could make a healthy addition to investors’ portfolios.

The article UnitedHealth Reports Healthy Q2 Earnings originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends UnitedHealth Group.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!